- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01386125
A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)
February 7, 2022 updated by: Organon and Co
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) in the Treatment of Nasal Polyps (Protocol No. P05604)
This study will evaluate the effectiveness and safety of MFNS in improving nasal congestion/obstruction and in reducing bilateral nasal polyps.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
748
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must be Chinese
- Must have a diagnosis of bilateral nasal polyps
- Clinically significant nasal congestion/obstruction must be present
- Must be in good health, free of any clinically significant disease that would interfere with the study schedule or procedures, or compromise the participant's safety
- Must have negative urine pregnancy test
- Must be using or agree to use a medically accepted method of contraception prior to Screening and during the study
Exclusion Criteria:
- Have a history of seasonal allergic rhinitis within the last two years
- Have had sinus or nasal surgery within the past six months
- Have presumed fibrotic nasal polyps
- Have had three or more nasal surgeries
- Have had any surgical procedure that prevents an accurate grading of the polyps
- Complete (or near complete) nasal obstruction
- Have acute sinusitis, concurrent nasal infection or have had a nasal infection within two weeks
- Have ongoing rhinitis medicamentosa
- Have Churg Strauss syndrome (vasculitis, asthma, fever, and eosinophilia)
- Have dyskinetic ciliary syndromes, eg, Young's syndrome (sinopulmonary infections and obstructive azoospermia) or Kartagener's syndrome (immobile cilia)
- Have been treated within the last 4 weeks with intranasal steroids
- Have used any investigational drug in the last 30 days
- Have a hypersensitivity to corticosteroids or are allergic to aspirin
- Have an ongoing upper respiratory tract infection or had an upper respiratory tract infection within two weeks
- Have a nasal septal deviation needing corrective surgery
- Have a nasal septal perforation
- Have asthma that required in-patient hospitalization for asthma control within six months, required ventilator support for respiratory failure secondary to their asthma within the last five years, required admission to the hospital for management of airway obstruction on two or more occasions within the past year, or required use of more than 14 days of systemic steroid use in previous six months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mometasone Furoate Nasal Spray (MFNS)
Participants receive mometasone furoate nasal spray (MFNS) 200 mcg twice daily (BID) for 16 weeks
|
MFNS, 200 mcg BID administered as two 50 mcg sprays in each nostril BID for up to 16 weeks
|
Placebo Comparator: Placebo
Participants receive matching placebo nasal spray BID for 16 weeks
|
Two sprays in each nostril BID for up to 16 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Congestion/Obstruction Score
Time Frame: Baseline and Weeks 1-4
|
At Baseline, the Investigator and participant jointly evaluated the signs and symptoms of congestion/obstruction.
After Baseline, participants scored the signs and symptoms of congestion/obstruction every morning immediately prior to dosing using a morning instantaneous congestion/obstruction score.
This score reflected the participant's condition at that time (instantaneous) and ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3= severe), with a lower score indicating less congestion/obstruction.
Congestion/obstruction scores were averaged over Weeks 1-4 of the treatment period.
Data are compared using Least Square (LS) Means.
LS Mean Change from Baseline = LS Mean Score averaged over Weeks 1-4 - LS Mean Score for Baseline.
|
Baseline and Weeks 1-4
|
Change From Baseline in Total Polyp Size Score
Time Frame: Baseline and Week 16
|
An endoscopic nasal examination was performed by the Investigator.
Bilateral nasal polyps were scored as follows for each notril (left and right): 0=no polyps, 1=polyps in middle meatus not reaching below inferior border of middle turbinate, 2=polyps reaching below inferior border of middle turbinate but not inferior border of inferior turbinate, 3=large polyps reaching to or below the lower borders of the inferior turbinate or polyps medial to the middle turbinate.
Total polyp size score ranged from 0 to 6 (scored 0 to 3 for each nostril), with a lower score indicating smaller-sized polyps.
LS Mean Change from Baseline = LS Mean Score for Week 16 - LS Mean Score for Baseline.
|
Baseline and Week 16
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2011
Primary Completion (Actual)
February 1, 2013
Study Completion (Actual)
February 1, 2013
Study Registration Dates
First Submitted
June 9, 2011
First Submitted That Met QC Criteria
June 29, 2011
First Posted (Estimate)
June 30, 2011
Study Record Updates
Last Update Posted (Actual)
February 16, 2022
Last Update Submitted That Met QC Criteria
February 7, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P05604
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nasal Polyps
-
Poitiers University HospitalNot yet recruiting
-
Ohio State UniversityActive, not recruitingChronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsUnited States
-
Johns Hopkins UniversityGlaxoSmithKlineTerminatedPatients With Nasal Polyps
-
GB001, Inc, a wholly owned subsidiary of Gossamer...CompletedChronic Rhinosinusitis Without Nasal Polyps (CRSsNP) | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)United States, Czechia, Ukraine
-
Optinose US Inc.CompletedBilateral Nasal PolyposisUnited States
-
St. Paul's Sinus CentreRecruitingAsthma | Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsCanada
-
Christiane HaaseActive, not recruitingAsthma | Chronic Rhinosinusitis (Diagnosis) | Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsDenmark
-
Centre hospitalier de l'Université de Montréal...RecruitingChronic Rhinosinusitis With Nasal PolypsCanada
-
SanofiRegeneron PharmaceuticalsCompletedChronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)Belgium, Mexico, Turkey, Israel, Spain, Sweden, Argentina, Canada, Japan, United States, Australia, Chile, Portugal, Russian Federation
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingChronic Rhinosinusitis With Nasal PolypsItaly
Clinical Trials on Mometasone Furoate Nasal Spray (MFNS)
-
Organon and CoCompleted
-
Organon and CoIntegrated Therapeutics GroupCompleted
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Insmed IncorporatedRecruitingChronic Rhinosinusitis Without Nasal PolypsUnited States, Australia, Argentina, Canada
-
Organon and CoCompleted
-
Organon and CoCompleted